DK3154543T3 - PPAR-Forbindelser til anvendelse ved behandlingen af fibrotiske lidelser - Google Patents
PPAR-Forbindelser til anvendelse ved behandlingen af fibrotiske lidelser Download PDFInfo
- Publication number
- DK3154543T3 DK3154543T3 DK15728018T DK15728018T DK3154543T3 DK 3154543 T3 DK3154543 T3 DK 3154543T3 DK 15728018 T DK15728018 T DK 15728018T DK 15728018 T DK15728018 T DK 15728018T DK 3154543 T3 DK3154543 T3 DK 3154543T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- fibrotic disorders
- ppar compounds
- ppar
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305896 | 2014-06-13 | ||
| EP14305895 | 2014-06-13 | ||
| EP14305894 | 2014-06-13 | ||
| EP14305897 | 2014-06-13 | ||
| EP14307187 | 2014-12-24 | ||
| PCT/EP2015/063196 WO2015189401A1 (en) | 2014-06-13 | 2015-06-12 | Ppar compounds for use in the treatment of fibrotic diseases. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3154543T3 true DK3154543T3 (da) | 2019-12-02 |
Family
ID=53373480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15728018T DK3154543T3 (da) | 2014-06-13 | 2015-06-12 | PPAR-Forbindelser til anvendelse ved behandlingen af fibrotiske lidelser |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10052311B2 (da) |
| EP (1) | EP3154543B1 (da) |
| JP (1) | JP6557684B2 (da) |
| KR (1) | KR102347721B1 (da) |
| CN (1) | CN106573058B (da) |
| AU (1) | AU2015273454B2 (da) |
| BR (1) | BR112016029129A2 (da) |
| CA (1) | CA2951337C (da) |
| CY (1) | CY1122264T1 (da) |
| DK (1) | DK3154543T3 (da) |
| EA (1) | EA036342B1 (da) |
| ES (1) | ES2755183T3 (da) |
| HR (1) | HRP20191941T1 (da) |
| HU (1) | HUE046293T2 (da) |
| IL (1) | IL249458B (da) |
| MX (1) | MX373268B (da) |
| PL (1) | PL3154543T3 (da) |
| PT (1) | PT3154543T (da) |
| RS (1) | RS59426B1 (da) |
| SI (1) | SI3154543T1 (da) |
| TN (1) | TN2016000535A1 (da) |
| UA (1) | UA120851C2 (da) |
| WO (1) | WO2015189401A1 (da) |
| ZA (1) | ZA201608281B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202092888A1 (ru) * | 2018-07-13 | 2021-04-19 | Кинарус Аг | КОМБИНАЦИИ АГОНИСТОВ PPAR И ИНГИБИТОРОВ КИНАЗЫ p38 ДЛЯ ПРЕДОТВРАЩЕНИЯ ИЛИ ЛЕЧЕНИЯ ФИБРОЗИРУЮЩИХ ЗАБОЛЕВАНИЙ |
| FR3084254B1 (fr) * | 2018-07-27 | 2020-10-23 | Inventiva | Derives deuteres du lanifibranor |
| CN110934866B (zh) * | 2018-09-25 | 2023-12-01 | 深圳微芯生物科技股份有限公司 | 西格列羧及其相关化合物的应用 |
| US11504380B2 (en) | 2019-11-08 | 2022-11-22 | Inventiva | Method of treatment of cirrhosis |
| WO2021161218A1 (en) * | 2020-02-11 | 2021-08-19 | Inorbit Therapeutics Ab | Sulfinic acid and sulfonic acid compounds for use in modulating peroxisome proliferator-activated receptors |
| EP4000616A1 (en) | 2020-11-17 | 2022-05-25 | Inventiva | Combination therapy for the treatment of a liver disease |
| WO2022122014A1 (zh) | 2020-12-11 | 2022-06-16 | 苏州科睿思制药有限公司 | Lanifibranor的晶型及其制备方法和用途 |
| CN114058694A (zh) * | 2021-11-29 | 2022-02-18 | 上海市普陀区中心医院 | Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用 |
| JP2025511354A (ja) | 2022-04-06 | 2025-04-15 | シャペロン インク. | タウロデオキシコール酸又はその薬学的に許容される塩を有効成分として含有する肺線維症の予防又は治療用組成物 |
| WO2023220332A1 (en) * | 2022-05-13 | 2023-11-16 | Children's Hospital Medical Center | Methods and compositions for treatment of idiopathic pulmonary fibrosis |
| WO2025217571A1 (en) * | 2024-04-12 | 2025-10-16 | Pliant Therapeutics, Inc. | Fixed dose combinations of integrin inhibitor with ppar agonists |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004103296A2 (en) | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| FR2890071B1 (fr) * | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| NZ567162A (en) | 2005-09-07 | 2011-06-30 | Plexxikon Inc | 1, 3-disubstituted indole derivatives for use as PPAR modulators |
| JP2007112720A (ja) * | 2005-10-18 | 2007-05-10 | Kissei Pharmaceut Co Ltd | メタボリックシンドローム予防又は治療薬 |
| JP5248747B2 (ja) * | 2006-01-19 | 2013-07-31 | キッセイ薬品工業株式会社 | アディポネクチン受容体発現賦活薬 |
| JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン, インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| EP2229951A1 (en) | 2009-03-08 | 2010-09-22 | Stichting Katholieke Universiteit | Methods for the treatment or prevention of systemic sclerosis |
| KR101865677B1 (ko) | 2009-11-26 | 2018-07-16 | 장피트 | 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도 |
| MX2012013574A (es) | 2010-05-26 | 2013-01-24 | Bayer Ip Gmbh | El uso de estimuladores de la sgc, activadores de la sgc, solos y en combinacion con inhibidores de la pde5 para el tratamiento de esclerosis sistemica (ecs). |
| WO2012159107A1 (en) | 2011-05-19 | 2012-11-22 | Rhode Island Hospital | Inhibition of renal fibrosis |
| KR20190135545A (ko) | 2011-10-28 | 2019-12-06 | 루메나 파마수티컬즈, 인코포레이티드 | 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제 |
| WO2013071077A1 (en) * | 2011-11-09 | 2013-05-16 | Cornell University | The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies |
| JP6293137B2 (ja) | 2012-07-18 | 2018-03-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 慢性腎臓病(ckd)を予防および処置するための方法 |
-
2015
- 2015-06-12 AU AU2015273454A patent/AU2015273454B2/en active Active
- 2015-06-12 CA CA2951337A patent/CA2951337C/en active Active
- 2015-06-12 WO PCT/EP2015/063196 patent/WO2015189401A1/en not_active Ceased
- 2015-06-12 PL PL15728018T patent/PL3154543T3/pl unknown
- 2015-06-12 PT PT157280181T patent/PT3154543T/pt unknown
- 2015-06-12 EP EP15728018.1A patent/EP3154543B1/en active Active
- 2015-06-12 SI SI201530986T patent/SI3154543T1/sl unknown
- 2015-06-12 US US15/318,553 patent/US10052311B2/en active Active
- 2015-06-12 HR HRP20191941TT patent/HRP20191941T1/hr unknown
- 2015-06-12 CN CN201580043674.2A patent/CN106573058B/zh active Active
- 2015-06-12 MX MX2016016534A patent/MX373268B/es active IP Right Grant
- 2015-06-12 KR KR1020167034694A patent/KR102347721B1/ko active Active
- 2015-06-12 BR BR112016029129-8A patent/BR112016029129A2/pt not_active Application Discontinuation
- 2015-06-12 UA UAA201612728A patent/UA120851C2/uk unknown
- 2015-06-12 HU HUE15728018A patent/HUE046293T2/hu unknown
- 2015-06-12 TN TN2016000535A patent/TN2016000535A1/en unknown
- 2015-06-12 EA EA201692433A patent/EA036342B1/ru unknown
- 2015-06-12 ES ES15728018T patent/ES2755183T3/es active Active
- 2015-06-12 RS RSP20191321 patent/RS59426B1/sr unknown
- 2015-06-12 JP JP2016572615A patent/JP6557684B2/ja active Active
- 2015-06-12 DK DK15728018T patent/DK3154543T3/da active
-
2016
- 2016-11-30 ZA ZA2016/08281A patent/ZA201608281B/en unknown
- 2016-12-08 IL IL249458A patent/IL249458B/en active IP Right Grant
-
2018
- 2018-07-24 US US16/043,976 patent/US10383858B2/en active Active
-
2019
- 2019-11-06 CY CY20191101159T patent/CY1122264T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| IL247452A0 (en) | Compounds for treatment of complement mediated disorders | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3154543T3 (da) | PPAR-Forbindelser til anvendelse ved behandlingen af fibrotiske lidelser | |
| IL257252A (en) | Methods of treating fgf21-associated disorders | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3433266T3 (da) | Fremgangsmåder til behandling af mitokondrieforstyrrelser | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3134084T3 (da) | Fremgangsmåde til behandling af lungeadenokarcinom | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| BR112016022976A2 (pt) | Métodos para o tratamento de hcv | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose | |
| DK3191513T3 (da) | Anvendelse af reslizumab til behandling af moderat til svær eosinofil astma | |
| DK3192524T3 (da) | Hgf præparat egnet til behandling af neurologiske lidelser | |
| DK3209295T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
| DK3125874T3 (da) | Et terapeutisk middel til anvendelse i behandlingen af infektioner | |
| DK3169405T3 (da) | Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme | |
| DK3855181T3 (da) | Forbindelser til behandling af lipofuscinrelaterede sygdomme | |
| DK3096775T3 (da) | SOCS-mimetika til behandling af sygdomme |